GCP ClinPlus is a leading full-service Contract Research Organization (CRO) with over 22 years of experience supporting global clinical development. Headquartered in China with an international presence through its U.S. subsidiary and strategic partners in Europe, the US and Latin America, GCP ClinPlus offers comprehensive solutions across the clinical trial lifecycle, including biometrics, site management, clinical operations, regulatory submissions, and specialized therapeutic expertise.
Since its inception in 2003, the company has successfully executed over 2,200 clinical projects and supported numerous IND, NDA, and global regulatory submissions across FDA, EMA, and NMPA. Through sustained capital investment and strategic expansions—including the formation of subsidiaries focused on CGT and endocrinology—GCP ClinPlus has built a robust operational network that seamlessly integrates research, regulatory, and commercialization capabilities.
Backed by multiple renowned investment institutions, GCP ClinPlus has stable financial resources that enable continuous innovation and operational resilience. The company has developed 110+ proprietary tools, holds over 60 software copyrights and 8 invention patents, and has a repurchase rate exceeding 65%. More than 35% of its staff hold PhD or Master's degrees, ensuring high technical competency and scientific rigor.
With a strong track record in CGT, infectious diseases, oncology, ophthalmology, immunology and medical device, and a history of supporting approvals for first-in-class drugs and breakthrough innovations, GCP ClinPlus is a trusted partner for biopharma companies aiming to accelerate development, access China’s vast patient pool, and achieve global regulatory success.
Leveraging access to large, treatment-naïve, and concentrated patient populations, we significantly accelerate recruitment timelines.
Our dedicated SSU team and extensive partner site network—including green access hospitals—streamline start-up with operational agility.
Our data and processes align with FDA, EMA, and NMPA standards, ensuring seamless global regulatory submission readiness.
We offer significantly lower trial costs compared to the U.S. and EU, with no compromise on quality.
Unlike large multinational CROs, we treat every client as a top priority—offering personalized service and dedicated attention.
We consistently deliver on timelines and budgets with integrity, full visibility, and proactive communication.
With over 22 years of clinical development experience, we offer tailored strategies to avoid trial pitfalls and ensure success.
We provide integrated support for global approvals and China commercialization, helping clients achieve cross-border development goals efficiently.
CEO, GCP ClinPlus Former Cardiovascular Surgeon
Recipient of two National Science and Technology Progress Awards
